[go: up one dir, main page]

SG11201509750VA - Polymorph forms of icotinib maleate and uses thereof - Google Patents

Polymorph forms of icotinib maleate and uses thereof

Info

Publication number
SG11201509750VA
SG11201509750VA SG11201509750VA SG11201509750VA SG11201509750VA SG 11201509750V A SG11201509750V A SG 11201509750VA SG 11201509750V A SG11201509750V A SG 11201509750VA SG 11201509750V A SG11201509750V A SG 11201509750VA SG 11201509750V A SG11201509750V A SG 11201509750VA
Authority
SG
Singapore
Prior art keywords
polymorph forms
icotinib maleate
icotinib
maleate
polymorph
Prior art date
Application number
SG11201509750VA
Inventor
Shaojing Hu
Wei Long
Fei Wang
Yinxiang Wang
Lieming Ding
Original Assignee
Betta Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Betta Pharmaceuticals Co Ltd filed Critical Betta Pharmaceuticals Co Ltd
Publication of SG11201509750VA publication Critical patent/SG11201509750VA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/056Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13Dicarboxylic acids
    • C07C57/145Maleic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201509750VA 2013-06-09 2014-06-09 Polymorph forms of icotinib maleate and uses thereof SG11201509750VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2013077093 2013-06-09
PCT/CN2014/079484 WO2014198210A1 (en) 2013-06-09 2014-06-09 Polymorph forms of icotinib maleate and uses thereof

Publications (1)

Publication Number Publication Date
SG11201509750VA true SG11201509750VA (en) 2015-12-30

Family

ID=52021656

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201509750VA SG11201509750VA (en) 2013-06-09 2014-06-09 Polymorph forms of icotinib maleate and uses thereof

Country Status (12)

Country Link
US (1) US9505774B2 (en)
EP (1) EP3008070B9 (en)
JP (1) JP6518655B2 (en)
KR (1) KR102263410B1 (en)
AU (1) AU2014280709B2 (en)
BR (1) BR112015030591B1 (en)
CA (1) CA2914854C (en)
ES (1) ES2656699T3 (en)
RU (1) RU2708079C9 (en)
SG (1) SG11201509750VA (en)
TW (1) TWI596098B (en)
WO (1) WO2014198210A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20022332A3 (en) * 2000-01-07 2003-01-15 Transform Pharmaceuticals, Inc. Sample assembly
US7078409B2 (en) * 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
CA2730311A1 (en) * 2008-07-08 2010-01-14 Beta Pharma Inc. Icotinib hydrochloride, synthesis, crystalline forms, drug combinations, and uses thereof
IN2014MN00842A (en) * 2011-10-31 2015-07-03 Betta Pharmaceuticals Co Ltd

Also Published As

Publication number Publication date
US9505774B2 (en) 2016-11-29
TWI596098B (en) 2017-08-21
EP3008070B1 (en) 2017-11-15
CA2914854A1 (en) 2014-12-18
CA2914854C (en) 2017-08-22
AU2014280709A1 (en) 2016-01-21
AU2014280709B2 (en) 2017-05-04
BR112015030591B1 (en) 2022-09-13
RU2708079C2 (en) 2019-12-04
US20160137658A1 (en) 2016-05-19
TW201512203A (en) 2015-04-01
ES2656699T9 (en) 2018-06-04
BR112015030591A2 (en) 2017-07-25
KR102263410B1 (en) 2021-06-10
EP3008070A1 (en) 2016-04-20
EP3008070B9 (en) 2018-05-23
ES2656699T3 (en) 2018-02-28
KR20160018711A (en) 2016-02-17
EP3008070A4 (en) 2016-08-10
RU2708079C9 (en) 2020-02-28
WO2014198210A1 (en) 2014-12-18
JP6518655B2 (en) 2019-05-22
JP2016520624A (en) 2016-07-14
RU2016100026A (en) 2017-07-20

Similar Documents

Publication Publication Date Title
IL287516A (en) Therapeutic uses of empagliflozin
IL241101A0 (en) Therapeutic uses of empagliflozin
IL241102B (en) Therapeutic uses of empagliflozin
LT2981271T (en) Therapeutic uses of empagliflozin
IL244268A0 (en) Heterocyclic compounds and methods of use
ZA201602198B (en) Preparation of hydroxy-benzylbenzene derivatives
PL3019477T3 (en) Heterocyclic compounds and methods of their use
ZA201604502B (en) Use of benzimidazole-proline derivatives
SG11201507389RA (en) Integration of hydro-dechlorination and hydro-regeneration
IL241290A0 (en) Sovaprevir polymorphs and methods of manufacture thereof
SG11201509753SA (en) New polymorphic forms of icotinib phosphate and uses thereof
SG11201509920UA (en) Polymorphic forms of icotinib and uses thereof
ZA201508951B (en) Polymorph forms of icotinib maleate and uses thereof
SG11201509750VA (en) Polymorph forms of icotinib maleate and uses thereof
TWM475821U (en) Structure of mosquito-catch
ZA201508950B (en) New polymorphic forms of icotinib phosphate and uses thereof
TWM476537U (en) Structure of kettle
PL3071575T3 (en) Preparation of normorphinans
HUE041663T2 (en) Production of myxopyronin and of its derivatives
TWM475524U (en) Structure of rivet-pulling
GB201304608D0 (en) BenTime of Yisrael operable arrangement